Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
PATIENT INTEREST AND NEEDS
Patients are interested in less frequent dosing
A global study highlights the challenges of daily therapy for people living with HIV
In multiple ViiV-sponsored and independent surveys, people living with HIV have expressed an interest in less frequent dosing.1-4 It was identified as one of the most important potential improvements in HIV therapy by patients.5
would prefer not having to take medication every day as long as their HIV stays suppressed.5
expressed interest in an injectable HIV treatment dosed less frequently than daily oral treatment.2,3
Understanding unmet needs in HIV therapy
A global study highlights the challenges of daily therapy for some people living with HIV
Positive Perspectives Wave 2 survey (PP2) is one of the largest, global, HIV patient-reported outcomes studies to date.*1 2,389 people living with HIV aged 18-84 across 25 countries took part in the study.1
The study reveals the experiences of people living with HIV, reflecting changes in HIV care and provides insights into aspects of quality of life that need to be addressed.1
The results of PP2 showed that for some patients, taking daily medication can affect their emotional wellbeing.1 Patients often don’t share the treatment challenges they face with their physicians.1
*The investigators involved received ethics approval and input from a steering committee of patient experts.
Fear of Disclosure1
hide or disguise their HIV medication
experience stress if someone finds their HIV medication
Anxiety with Staying Adherent1
say remembering to take daily HIV treatment causes stress or anxiety
A Daily Reminder of HIV1
are reminded of HIV in their life when taking tablets
are reminded of bad experiences from their past when taking tablets
Changing the experience of HIV Therapy
- De los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the Positive Perspectives Study. AIDS Behav. Published online ahead of print: October 7, 2020. Doi: 10.1007/s10461-020-03055-1.
- Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). 2013;8(11):1807-1813.
- Derrick B, Ostermann J, Weissman SB, et al. Who wants to switch? Gauging patient interest in novel antiretroviral therapies. Open Forum Infect Dis. 2018;5(10):ofy247.
- Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020; 382:1112-1123 doi: 10.1056/NEJMoa1904398.
- De los Rios P, Okoli C, Young B, et al. Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries. Popul Med. 2020; 2: 23. doi: https://doi.org/10.18332/popmed/
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.
All other trademarks are owned by the ViiV Healthcare group, or its licensor.
©2023 GSK group of companies. All rights reserved.
PM-IE-CBR-WCNT-230006
Date of preparation: September 2023
